MRKR (Marker Therapeutics) Total Current Assets : $22.02 Mil (As of Dec. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Marker Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Marker Therapeutics's total current assets for the quarter that ended in Dec. 2024 was $22.02 Mil.

Marker Therapeutics Total Current Assets Historical Data

The historical data trend for Marker Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marker Therapeutics Total Current Assets Chart

Marker Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Current Assets

Get a 7-Day Free Trial

24.41

45.98

16.62

17.13

22.02

Marker Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Current Assets	Get a 7-Day Free Trial															17.13	14.09	11.68	10.91	22.02

Marker Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Marker Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	19.192	+	2.347	+	0	+	0.484
	=	22.02

Marker Therapeutics's Total Current Assets for the quarter that ended in Dec. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	19.192	+	2.347	+	0	+	0.484
	=	22.02

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Marker Therapeutics (NAS:MRKR) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Marker Therapeutics's Liquidation Value for the quarter that ended in Dec. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	19.192	-	3.464	+	0.75 * 0	+	0.5 * 0
=	15.73

Marker Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Marker Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (NAS:MRKR) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

GX1:Germany

Address

2450 Holcombe Boulevard, Suite e BCM-A, MS: BCM251, Houston, TX, USA, 77021

Website

https://www.markertherapeutics.com

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Executives

New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Steve Elms	director	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Eliot M Lurier	officer: Interim CFO	C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Katharine Knobil	director	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Frederick Gerald Wasserman	director	4 NOBADEER DRIVE, PENNINGTON NJ 08534
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Peter L. Hoang	director, officer: CEO and President	C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani	director	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Norman David Eansor	director	8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
Forest Baskett	10 percent owner
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043